Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (CMPS), Liquidia Technologies (LQDA) and Regulus (RGLS)

TipRanks

May. 12, 2025, 04:43 AM

Analysts have been eager to weigh in on the Healthcare sector with new ratings on COMPASS Pathways (CMPS – Research Report), Liquidia Technologies (LQDA – Research Report) and Regulus (RGLS – Research Report).

Protect Your Portfolio Against Market Uncertainty

Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

COMPASS Pathways (CMPS)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways today and set a price target of $45.00. The company’s shares closed last Friday at $3.79, close to its 52-week low of $2.88.

According to TipRanks.com, Trucchio ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.8% and a 29.3% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $18.75, which is a 406.8% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $23.00 price target.

See today’s best-performing stocks on TipRanks >>

Liquidia Technologies (LQDA)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Liquidia Technologies, with a price target of $29.00. The company’s shares closed last Friday at $15.26.

According to TipRanks.com, Fein is a 1-star analyst with an average return of -0.5% and a 39.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Day One Biopharmaceuticals.

Liquidia Technologies has an analyst consensus of Strong Buy, with a price target consensus of $28.13, representing an 81.1% upside. In a report issued on May 2, LifeSci Capital also maintained a Buy rating on the stock with a $35.00 price target.

Regulus (RGLS)

Wells Fargo analyst Yanan Zhu maintained a Hold rating on Regulus on May 8 and set a price target of $9.00. The company’s shares closed last Friday at $7.87.

According to TipRanks.com, Zhu has 0 stars on 0-5 stars ranking scale with an average return of -9.3% and a 23.9% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Hold analyst consensus rating for Regulus with a $8.80 average price target, a 12.4% upside from current levels. In a report issued on April 30, Canaccord Genuity also downgraded the stock to Hold with a $11.00 price target.

Read More on CMPS:

Disclaimer & Disclosure Report an Issue